Combination of C012 with PI-103 or rapamycin yielded a marginally significant reduction in cell viability in Mel-JD and MM200 cell lines (Figure 2A iv–v ) and low additive BLISS scores (Figure 2B ).
← all excerpts
A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner.
1
—
—